Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.95
MADRIGAL PHARMACEUTICALS, INC. amended term loan of aggregate of $250.0 million in term loans; Tranche 2 increased by $15.0 million to $65.0 million; Tranche 4 reduced by $ with Hercules Capital, Inc. at variable per annum rate determined based on the greater of (i) the prime rate as maturing May 1, 2026, extendable for one year upon Approval Milestone.
- Instrument
- term loan
- Principal
- aggregate of $250.0 million in term loans; Tranche 2 increased by $15.0 million to $65.0 million; Tranche 4 reduced by $
- Counterparty
- Hercules Capital, Inc.
- Rate
- variable per annum rate determined based on the greater of (i) the prime rate as
- Maturity
- May 1, 2026, extendable for one year upon Approval Milestone
- Event
- amendment
Exact text from the filing
nt, dated May 9, 2022 (the “Loan Agreement” and as amended by the Amendment, the “Amended Loan Agreement”), with the several banks and other financial institutions or entities party thereto (each, a “Lender” and collectively referred to as the “Lenders”), and Hercules Capital, Inc., a Maryland corporation (“Hercules”), as Lender and in its capacity as administrative agent and collateral agent for the Lenders (in such capacity, “Agent”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.99
MADRIGAL PHARMACEUTICALS, INC. amended First Amendment to the Loan and Security Agreement with Hercules Capital, Inc., as Lender and Agent valued at $250.0 million (effective 2023-02-03).
- Action
- amendment
- Agreement
- credit facility
- Counterparty
- Hercules Capital, Inc., as Lender and Agent
- Value
- $250.0 million
- Effective
- 2023-02-03
Exact text from the filing
entered into a First Amendment (the “Amendment”) to the Loan and Security Agreement, dated May 9, 2022 (the “Loan Agreement”
View on SEC.gov